Study of Immune Response to Cytomegalovirus and Epstein-Barr Virus in Patients Undergoing Haploidentical Stem Cell Transplantation with CMV Prevention

What this Trial Is About

Researchers are evaluating the immune system recovery specific to cytomegalovirus CMV and Epstein-Barr virus EBV in patients with hemopathy who undergo haploidentical hematopoietic stem cell transplantation haplo-HSCT. The study focuses on how well the immune system reestablishes itself while patients receive preventative treatment against cytomegalovirus. This observational, single-center study aims to better understand immune responses in this patient group. The study involves testing participants CMV and EBV specific cell-mediated immunity CMI before the conditioning treatment and at several points after transplantation 30, 45, 60, 90, 120, and 180 days. These tests help track immune recovery and response over time. This study does not involve experimental drug treatments but monitors immune function as part of the transplant care process. Participants will be monitored for immune responses through blood tests at scheduled intervals. Researchers will measure key outcomes such as CMV and EBV CMI at 6 months post-transplant and track virus reactivation rates, survival, relapse, and complications like graft-versus-host disease up to one year after transplantation. The total follow-up period includes assessments up to 12 months to evaluate long-term immune status and patient outcomes.

Evaluation of CMV/EBV-CMI in Haploid HSCT